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Autoantibodies (aAB) to the presynaptic located enzyme glutamate decarboxylase 
65 (GAD65) are a characteristic attribute for a variety of autoimmune diseases of the 
central nervous system including subtypes of limbic encephalitis, stiff person-syndrome, 
cerebellar ataxia, and Batten’s disease. Clinical signs of hyperexcitability and improve-
ment of disease symptoms upon immunotherapy in some of these disorders suggest 
a possible pathogenic role of associated aAB. Recent experimental studies report 
inconsistent results regarding a direct pathogenic influence of anti-GAD65 aAB affecting 
inhibitory synaptic transmission in central GABAergic pathways. We here provide a 
method for direct evaluation of aAB-induced pathomechanisms in the intact hippocampal 
network. Purified patient IgG fractions containing aAB to GAD65 together with fixable 
lipophilic styryl dyes (FMdyes) are stereotactically injected into the hilus and the dentate 
gyrus in anesthetized mice. Twenty-four hours after intrahippocampal injection, acute 
hippocampal slices are prepared and transferred to a patch-clamp recording setup 
equipped with a fluorescence light source. Intraneural incorporated FMdyes show 
correct injection site for patch-clamp recording. Whole-cell patch-clamp recordings 
are performed from granule cells in the dentate gyrus and extracellular stimulation is 
applied in the border area of the dentate gyrus-hilus region to stimulate GABAergic 
afferents arising from parvalbumin positive basket cells. GABA-A receptor mediated 
inhibitory postsynaptic currents (IPSC) and miniature IPSC are recorded after blocking 
glutamatergic transmission. This approach allows investigation of potential aAB-induced 
effects on GABA-A receptor signaling ex vivo in an intact neuronal network. This offers 
several advantages compared to experimental procedures used in previous studies by 
in vitro AB preincubation of primary neurons or slice preparations. Furthermore, this 
method requires only small amounts of patient material that are often limited in rare 
diseases.
Keywords: autoantibody, stereotactic injection, hippocampus, patch-clamp recording, limbic encephalitis, 
GAd65, GABAergic inhibition
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Introduction
IgG autoantibodies (aAB) to the glutamate decarboxylase 65 
(GAD65) are increasingly recognized in neurological diseases of 
the central nervous system, e.g., in stiff person-syndrome (SPS) (1, 
2), limbic encephalitis (3), Batten’s disease (4), or cerebellar ataxia 
(5). GAD65 is the rate limiting enzyme for GABA synthesis in 
presynaptic nerve endings of GABAergic interneurons (6). Signs 
of hyperexcitability or reduced central inhibition in these disorders 
point toward a potential pathogenic role of the associated aAB 
to GAD65 (7, 8). However, there are several concerns arguing 
against direct pathogenic mechanisms induced by the patient’s 
aAB to GAD65. First, clinical syndromes are diverse and different 
regions and networks in the CNS seem to be afflicted, e.g., the 
hippocampus and amygdala in the subgroup of anti-GAD65 aAB 
positive limbic encephalitis, the brainstem and spinal cord in SPS, 
or the cerebellum in cerebellar ataxia (5). Second, GAD65 is an 
intracellular located enzyme that is less likely accessible to aAB 
compared to antigens on the neuronal surface. Third, in many 
of these syndromes exists a concurrent immune response to a 
variety of neuronal antigens in addition to GAD65. In SPS, patients 
with aAB to GAD65 develop often additional AB to the GABA-A 
receptor associated protein (GABARAP) (9). In Batten’s disease, 
aAB to several antigens are described, e.g., to alpha-fetoprotein 
and further, still unknown neuronal antigens (10). So, if there are 
specific pathogenic mechanisms induced by aAB, it is uncertain 
which of the disease associated aAB causes disease symptoms. 
There are several experimental studies investigating patient derived 
IgG targeting GAD65 in neurons in different settings (8, 11, 12). 
However, results obtained from these studies are heterogeneous 
and sometimes contrasting. In  vitro studies using dissociated 
neuronal cell cultures reported reduced GABAergic inhibitory 
synaptic transmission upon preincubation with patient IgG con-
taining anti-GAD65 aAB (13). In a recent study, we could provide 
evidence patient IgG derived from patients with SPS induced 
disturbance of GABAergic transmission. However, this was not 
caused by associated aAB to GAD65 but by IgG to another, yet 
unknown presumably presynaptic antigen that is included in the 
IgG fraction of these patients (14). In animal studies, patient IgG 
with high titers of aAB to GAD65 was reported to induce disturbed 
GABAergic inhibition in the spinal cord, cerebellum, or cortical 
areas (8, 15, 16). However, the target-specificity of IgG-induced 
pathophysiology to GAD65 remains to be shown. This can be 
achieved by use of recombinant, specific IgG derived from isolated 
human plasma cells in animal passive-transfer models as shown 
before for aAB to aquaporin 4 in mouse models for neuromyelitis 
optica (17, 18). Another approach is the use of affinity-purified 
IgG aAB extracted of the polyclonal patient IgG fraction (19–21).
However, patient-derived material is often limited because 
many of these syndromes are rare diseases with only few affected 
patients. Invasive interventions required obtaining patient mate-
rial, e.g., lumbar punction for cerebrospinal fluid (CSF) cannot 
be performed repetitively in those patients for ethical reasons.
Here, we propose a method to investigate direct aAB induced 
effects ex vivo after stereotactic application of patient IgG 
preparations into the hippocampal compartment using only very 
limited amounts of patient material. We describe the possibility 
of histological and electrophysiological analyses of GABAergic 
pathways in this passive-transfer mouse model.
Methods
Purification of Antibody-Containing IgG 
Fractions
IgG of an example patient with SPS and high titers of anti-GAD65 
antibodies in serum and CSF as well as control IgG fractions 
without specific antineuronal reactivity were purified from 
therapeutic plasma exchange material by separation on exchange 
chromatography. Clinical details of the patients have been reported 
previously (16). The IgG fraction was concentrated by passage 
of the eluate through a Dialflo ultrafilter membrane (YM 100; 
Amicon, Witten, Germany) under nitrogen pressure to a volume 
of 50 ml. After dialysis against 10 l of water, the IgG sample was 
freeze-dried and stored at −20°C. Before use, lyophilized IgG was 
dissolved in 0.9M saline to a concentration of 5 mg/ml (16, 20).
stereotactic Injections of Patient IgG Fractions 
into the hippocampus of Mice
All animal experiments have been approved by the Thuringian 
state authorities (authorization # 02-059/13). Before surgery, 
the injection glass pipette (Glass Capillaries for Nanoliter 2000; 
Order# 4878; WPI, Sarasota, FL, USA) has been pulled with a long 
taper using a micropipette puller (Micropipette Puller P-1000; 
Sutter, Novato, CA, USA). The tip was then cut to a diameter of 
about 10 μm with a fine scissor. The injection pipette was attached 
to the head of a microprocessor-controlled nanoliter injector 
(Nanoliter 2000+ SYS-Micro4 Controller; WPI, Sarasota, FL, 
USA) and slightly filled with immersion oil to assure consistent 
pressure release onto the fluid by the injector. Thereafter, the 
pipette was completely filled with purified patient IgG fractions 
containing aAB against GAD65 (protein concentrations of 5 mg/
ml in 0.9M saline). Together with the IgG fractions, 1  mM of 
FM1-43FX-dye (life technologies, Darmstadt, Germany) was 
added for fluorescent labeling of the area that has been targeted 
by the stereotactic intrahippocampal injection. A 6- (electrophysi-
ological experiments) or 8-week-old (other experiments) wild type 
C57BL/6 mice were anesthetized with 1.5–2.0% isoflurane/oxygen 
and their head was fixed to a stereotactic apparatus (Figure 1; Lab 
StandardTM; Stoelting, Wood Dale, IL, USA). The temperature of 
the animals was monitored rectally and adjusted to 37°C by a 
heating pad with feedback control (FHC, Bowdoin, Canada). Eye 
ointment was used to prevent corneal drying during the surgery 
and the head was shaved with a razorblade. The skull was exposed 
by a small midline skin incision and the stereotactic injection sites 
were marked according to the respective coordinates (Table 1) 
determined according to the Paxinos mouse atlas (22). Holes were 
carefully drilled into the skull with a dentist driller (Foredom, 
Bethel, CT, USA) using drill heads of 0.47 mm diameter (Harvard 
Apparatus, Cambridge, UK) under visual control with an Olympus 
stereomicroscope (Olympus SZ 60, Tokyo, Japan). Care was taken 
not to penetrate the dura to avoid injury of the first cortical layers. 
For visual control of injection volumes, the initial maximum fluid 
level in the pipette was marked before each injection. The injec-
tion pipette was carefully moved to the respective injection point 
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according to the coordinates (Table 1; Figure 1). After waiting 
1 min, 1 μl of purified patient IgG solution together with fixable 
lipophilic styryl dyes (FMdyes) was injected into each hole with 
an injection speed of 4  nl/s. If the injection of solutions failed 
because the pipette was clogged by brain tissue, the injection 
pipette was removed and the injection was repeated with a new 
injection pipette. In some cases, minimal dorsal-ventral movement 
of the injection pipette was sufficient to perform proper injection 
without changing the pipette. After injection, the pipette was left 
in place for additional 5–10 min, before slowly being withdrawn. 
Thereafter, the skin was sutured with surgical suture (Covidien 
Sofilk 3-0, Dublin, Ireland) and the animals were monitored on a 
heating pad until complete recovery from anesthesia. All animals 
FIGure 1 | experimental setup for stereotactical injections of 
patient IgG fractions into the mouse hippocampus. (A) Stereotactic 
frame with two arms (one for fixation of the injection pipette, one for fixation 
of a marker). (B) Heating pad with a feedback mechanism and a rectal 
probe to maintain the physiological temperature of 36°C of the mouse 
during surgery. (C) Dentist driller with a drill head of 0.47 mm diameter. 
(d,e) Micro4-controller for injection of nanoliter volumes with the injection 
pipette. (F) Binocular for optical control of all experimental steps. (G) Inset 
showing the mouse skull during surgery. Intracranial holes are already 
drilled. The upper part shows the glass injection pipette with the fine taper 
and filled with oil and IgG solution during injection into one of two holes of 
the mouse skull.
tABle 1 | Coordinates for injections of IgG preparations in different parts 
of the hippocampal formation in mice (from bregma in mm).
target Anterior-
posterior
Medial-
lateral
distal- 
ventral
Middle dentate gyrus (front end) 2.2 1.2 2.0
Middle dentate gyrus (tale end) 2.2 2.0 2.0
End dentate gyrus (front end) 2.5 1.5 2.0
End dentate gyrus (tale end) 2.5 2.5 2.5
Middle CA1 region 2.2 2.0 1.5
End CA1 region 2.5 2.3 2.0
were sacrificed 1–4 days after surgery for immunohistological or 
electrophysiological experiments.
In a subset of animals, we injected 1 μl of a 0.4% trypan blue 
solution (Sigma-Aldrich, St. Louis, MO, USA) in the same way as 
described above to verify correct injection sites of stereotactic injec-
tion procedure (Figure 2). Here, 2–4 h after injection, the animals 
were sacrificed and the brain was cut in 1 mm slices with a tissue 
chopper (McIlwain Tissue Chopper, Mickle Laboratory Engineering 
Co Ltd., Guildfort, UK) and the ex vivo slices were directly viewed 
under a stereomicroscope (Zeiss Stemi SV6, Zeiss, Jena, Germany).
Immunohistology of IgG-Injected Brain slices
At 3–4 days post-injection, mice were deeply anesthetized, and 
intracardiac perfusion was performed. A catheter was placed into 
the left cardiac ventricle, and mice were perfused with 10 ml of 
phosphate buffered saline (PBS) followed by 4% paraformaldehyde 
(PFA) in phosphate buffer. Brains were extracted, afterfixated for 
24 h in 4% PFA, dehydrated for 24 h in 10% sucrose, then further 
24 h in 30% sucrose. Thereafter, 40 μm serial sections were prepared 
on a freezing sliding microtome (HM 450 Sliding Microtome; 
Thermo Scientific, Waltham, MA, USA). Slices were stored in 
anti-freeze solution (30% ethylene glycol, 700 mM glucose, 3 mM 
sodium azide in phosphate buffer, pH 7.4) at −20°C until the 
day of staining. Slices were then defrosted at room temperature 
FIGure 2 | hippocampal stainings after stereotactic injections of 
trypan blue or anti-GAd65 aAB containing IgG preparations.  
(A) Injection of 1 μl trypan blue in the dentate gyrus of each hemisphere 
shows uniform distribution exclusively in the hippocampal compartment. On 
the left side, the injection channel can be identified. (B) Immunohistological 
staining of injected anti-GAD65 aAB containing IgG preparation shows 
specific staining of cells in the dentate gyrus and around the injection channel 
(scale bar: 100 μm). (C) Dendrites of a CA1 pyramidal cell can be analyzed 
after injection of anti-GAD65 aAB containing IgG preparations. The 
magnification of dendrites at the branching region of a CA1 neuron [white 
box shown in (d)] shows staining of human IgG deposits with distinct spots 
distributed along the dendrite (scale bar: 20 μm).
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and washed six times for 15  min in tris-buffered saline (TBS). 
Unspecific binding sites were blocked by 3% normal goat serum 
and 2% milk powder in TBS containing 0.1% of Triton-X100 for 
permeabilization of the membrane for 30 min. Slices were incu-
bated with Cy3 goat anti-human antibodies (Dianova, Hamburg, 
Germany) as secondary antibodies to detect binding of the injected 
human aAB in 3% normal goat serum, 2% milk powder, and 0.1% 
TritonX-100 overnight at 4°C. After additional washing, steps in 
TBS for 10 min slices were placed on object slides, dried on air, 
stained for 5  min in DAPI solution (Sigma-Aldrich, St. Louis, 
MO, USA), washed three times in PBS for 5 min, and mounted 
with Fluoromount (Southern Biotech, Birmingham, AL, USA).
Confocal Microscopy
Cells were viewed on a confocal microscope (Zeiss LSM 710, Jena, 
Germany) using a 10× objective or a 63× oil objective, keeping 
laser power and photomultiplier tube voltage constant. Maximum 
projections of z-stacks were generated using FIJI image analysis 
software.
Acute hippocampal slice Whole-Cell  
Patch-Clamp recordings
Separate groups of mice were used for ex vivo acute brain-slice 
recording. Twenty-four hours after intrahippocampal IgG injec-
tion, mice were deeply anesthetized and decapitated. The brain was 
removed in ice-cold extracellular artificial CSF (ACSF 1; 40 mM 
NaCl, 25 mM NaHCO3, 10 mM glucose, 150 mM sucrose, 4 mM 
KCl, 1.25 mM NaH2PO4, 0.5 mM CaCl2, 7 mM MgCl2; purged with 
95% CO2/5% O2) and cut in two halves. The bulbus olfactorius was 
cut in a coronar manner and the brain was glued with the cut face 
onto the probe-holder with superglue (UHU, Bühl, Germany). 
Three hundred micrometer thick coronal slices were made with 
a vibratome (Leica, Wetzlar, Germany; Leica VT1200 S) with an 
amplitude of 1 mm and a velocity of 0.4 mm/s. Slices were trans-
ferred into an incubation beaker with extracellular ACSF suited for 
patch-clamp recording (ACSF 2; 125 mM NaCl, 25 mM NaHCO3, 
25 mM glucose, 2.5 mM KCl, 1.25 mM NaH2PO4, 2 mM MgCl2; 
purged with 95% CO2/5% O2) and held at 34°C for at least 30 min. 
For recordings, slices were then transferred into a measurement 
chamber (Figure 3) superfused with extracellular ACSF 2 with 
1.3–1.8 ml/min at room temperature. Recording electrodes pulled 
from thick-walled borosilicate glass (2.0 mm diameter; Science 
Products, Hofheim, Germany) were filled with intracellular record-
ing solution containing 140  mM KCl, 10  mM HEPES, 10  mM 
EGTA, 2 mM Na2ATP, 2 mM MgCl2, pH 7.2, and an osmolarity 
of 300–330  mOsmol. Recording electrodes had a final resist-
ance of 3–5 MΩ. Inhibitory postsynaptic currents (IPSCs) were 
recorded with an EPC10 patch clamp amplifier and Patch-Master 
Software (HEKA, Lambrecht, Germany). Whole-cell patches were 
performed of granule cells (GC) held at −70 mV. Recordings were 
rejected if the resting potential was more positive than −50 mV or 
changed during the experiments and if series resistance was higher 
than 20 MΩ. Acceptable membrane capacitance range is from 10 to 
30 pF. Evoked IPSCs were isolated by blocking glutamatergic trans-
mission using 10 μM Cyano-Nitroquinoxaline-Dione (CNQX) and 
50 μM 2-amino-phosphonovaleric acid (AP-5; Tocris Bioscience, 
Ellisville, MO, USA). Application of 1 μM tetrodotoxin (TTX; 
Sigma Aldrich, St. Louis, MO, USA) was used for recordings of 
miniature IPSCs (mIPSCs). Monosynaptic IPSCs were evoked as 
described previously (14, 20). Briefly, GABAergic synaptic inputs 
in whole-cell clamped GCs were evoked by another glass electrode 
filled with extracellular ACSF 2 that has been placed nearby a 
neighboring CG located toward the hilar region using a stimulus 
isolation unit (Isoflex, A.M.P.I, Jerusalem, Israel) (Figures  3 
and 4). In this configuration, GABAergic afferents arising from 
GABAergic basket cells (BC) located at the hilus border region are 
stimulated. Here, we applied pulses of 200 μs duration at 0.3 Hz 
while measuring IPSCs of the postsynaptic clamped GCs. Paired-
pulse recordings were obtained by stimulating the neurons with an 
inter-stimulus interval of 100 ms. Recordings were filtered at 2.9 
and 10 kHz using the filters of the amplifier. Traces were analyzed 
by Igor Pro Software (Wavemetrics, Lake Oswego, OR, USA).
results
trypan Blue Injections show labeling of the 
hippocampal Formation After stereotactic 
Injection
For direct ex vivo verification of the distribution of injected sub-
stances within the mouse brain, we injected trypan blue solution 
at different stereotactic coordinates (Table 1) into the hippocampal 
formation of both hemispheres (Figure  1). The distribution of 
trypan blue is shown in Figure 2A. The trypan blue labeling was 
FIGure 3 | experimental setup for whole-cell patch-clamp 
measurements in acute brain slices. An upright microscope (A) is placed 
on a X–Y table and is now freely movable around the bath-chamber (F) and the 
micromanipulators [(B), control unit: (d)]. The inset shows a magnification of 
the bath chamber with the perfusion system (K) of the bath and a grid holding 
the brain slice in the middle of the chamber (G). The recording and stimulation 
electrodes are marked with (I,J), respectively. The recording electrode is 
connected to a grounding electrode (h) as well as to the amplifier (e). The 
stimulation electrode is connected to the stimulator (C) which is triggered by 
the amplifier with a 5 mV stimulus command.
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apparent in most parts of the hippocampal formation including the 
dentate gyrus and major parts of the CA-regions. In this example, 
the injection channel can also be identified. This example also 
demonstrates that only minor lesions of the cortical and hip-
pocampal tissue result by the injection procedure using thin glass 
pipettes. Beside a slight diffusion of trypan blue along the lateral 
ventricle, brain compartments surrounding the hippocampus were 
not labeled.
detection of human IgG deposition After 
stereotactic Intrahippocampal Injection
Deposition of human IgG was tested 1–3 days after stereotactic 
injection by using fluorescence coupled commercial antibodies 
directed to human IgG. Immunohistology was performed in 
brain slices after perfusion and fixation. Detection of the 10 μg 
injected human IgG fractions with high titers of anti-GAD65 
aAB resulted in exclusive hippocampal immunoreactivity 
(Figure  2B). Neuronal dendrites in the injection site showed 
synaptic staining (Figures 2C,D). Magnification of the dendrites 
as shown here by high-resolution confocal microscopy demon-
strates that detailed morphological analysis and quantifications 
of dendritic structures including spines and synaptic spots are 
possible (Figure 2D). This method can also be combined with 
co-immunostaining of further synaptic markers. In comparison 
to the trypan blue stainings, the overall diffusion of the injected 
antibodies seems to be less widespread. This could be due to 
decreased concentrations of injected aAB in the more distant 
areas of the injection site, absorption of anti-GAD65 aAB by 
antigens near the injection site, or due to the higher viscosity of 
the IgG solution.
electrophysiological recordings and GABAergic 
synaptic transmission in the Perforans-Path –  
Granule Cell synapse is not Affected by 
stereotactic IgG Injection
Simultaneous injection of patient IgG fractions together with FM1-
43FX-Dye allows precise control of the injection site in vital ex vivo 
acute brain slice preparations. FM1-43FX-Dye is fluorescent in 
contact with cellular membranes and gets incorporated by activity-
dependent synaptic vesicle endocytosis. Therefore, the area of IgG 
injection can be determined in the vital hippocampal slices by 
localizing the FM1-43FX fluorescence (Figure 4A). The brain slices 
in this fluorescence labeled area seemed healthy without signs 
of swelling or tissue destruction. The neurons inside that region 
showed a healthy shape.
Electrophysiological measurements of IPSCs in GCs also 
showed reliable vitality in mice injected with control IgG fractions 
without specific antineuronal reactivity together with FM1-43FX 
dye. GC had the expected values of resting potential, input resist-
ance, and membrane capacity. Figures 4B,C show averaged sample 
traces of evoked GABAergic IPSCs after single and paired-pulse 
stimulation of the perforant path with a time interval of 100 ms. 
The GABAergic currents in FM1-43FX-injected brain slices had 
similar amplitudes of 145 pA (mean of 30 sweeps) and kinetics (rise 
time = 1.27 ms; decay time = 20.05 ms) as in untreated animals. 
The paired-pulse experiments revealed a significant depression 
of IPSCs after the second pulse due to the expected short-term 
plasticity dependent on incomplete vesicle recycling 100 ms after 
the first induced IPSC (ratio A2/A1 = 0.84). This is in line with 
published findings on IPSC depression in normal brain slices after 
extracellular stimulation or in paired recordings of GCs and BCs 
FIGure 4 | recording of GABAergic currents in dentate gyrus granule 
cell (GC)–basket-cell (BC) synapse. (A) Intravital fluorescent labeling of an 
IgG injection site in the apex of the dentate gyrus by FM1-43FX coinjection in 
a 300-μm mouse brain slice 24 h after injection. (B) Representative 
recordings of a single-evoked IPSC from a dentate gyrus GC after electric 
stimulation of a neighboring BC. (C) Paired-pulse depression of IPSCs of the 
same cell as shown in B with an interpulse interval of 100 ms. (d) Trace 
showing mIPSCs in a dentate gyrus GC after injection of control IgG.
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(14, 23). Recordings of mIPSCs in the control IgG injected brain 
slices show mean amplitude of 24 pA with a frequency of 0.41 Hz in 
a similar magnitude as mIPSCs of untreated animals (Figure 4D).
discussion
The in  vivo stereotactic intrahippocampal injection of small 
volumes offers several advantages in comparison to previously 
used passive-transfer methods of human IgG samples. First, this 
method is target-specific for the hippocampal formation as we 
could demonstrate by trypan blue staining and immunohistology 
detecting human IgG depositions. This selective delivery of IgG 
allows investigation of direct aAB effects on hippocampal function, 
e.g., learning and memory without interference of aAB-induced 
pathomechanisms in other regions of the CNS. Second, the surgi-
cal procedure is fast, and after completing the injections, animals 
are not affected by any implanted material as it is the case for 
chronic application of IgG by intraventricular administration using 
osmotic pumps (24) or by repetitive application using implanted 
intrathecal (20, 21) or intraventricular (15) catheters. Third, the 
required amounts of rare human IgG samples are much lower 
as compared to the other passive-transfer techniques. Moreover, 
the tissue destruction due to the injection procedure using glass 
capillaries with thin taper is clearly less compared to implantation 
of intracerebral catheters.
The parallel application of FM1-43FX fluorescence dyes makes 
this procedure exceptional suited for ex vivo brain slice recordings. 
Injection sites can be easily identified using a conventional fluo-
rescence light source on the recording setup. As mentioned, tissue 
destruction is minimal and extracellular as well as patch-clamp 
recordings can be performed without limitations in regions that 
have been visually identified by FMdye staining. However, one has 
to take into account that there might be a difference in the deposition 
of IgG and FMdye staining. Comparison of immunohistochemical 
detection of injected human IgG and fluorescent FMdyes are recom-
mended in pilot experiments to test the co-distribution of FMdye 
and IgG in the injected brain areas. Example recordings shown 
here demonstrate that GABAergic pathways, e.g., the monosynaptic 
transmission from BC located in the hilus projecting to dentate 
gyrus GC can be investigated without any differences in parameters 
of evoked IPSC and mIPSC as compared to recordings obtained 
from sham animals that were not injected (20). Here, we used six 
to eight-week-old mice for injection and recording. In principle, 
also mice older than 8 weeks can be used in this procedure. Please 
note that patch-clamp neurophysiology may be more difficult in 
older animals due to more rigid connective tissue.
Certainly, there are also limitations of this procedure. 
Implantation of osmotic pumps or intrathecal catheters allows 
continuous or easy repetitive application in the subarachnoidic 
space or into the brain parenchyma. Here, repetitive injections 
can be performed in principle but animals need to be anesthetized 
again. There is no need for additional trepanation but the skull 
has to be exposed and skin has to be opened and closed again 
which increases risk of infections. Further, optimal concentra-
tions of IgG solutions are not determined and can only be varied 
within the small injection volumes. Preliminary experiments 
may be necessary to obtain a dose-response curve. It is possible 
to inject up to 3 μl of IgG into one hemisphere (for example, three 
separate holes, 1 μl into each) without relevant tissue destruction. 
Another possibility is to inject 2 μl of IgG per hemisphere with 
repeated injections of IgG every day over total 3 days. The IgG 
concentrations can range from 2 to 10 mg/ml IgG. Even higher 
concentrations of IgG may be tested until clogging of the pipette 
tip occurs due to the increased viscosity of the solution.
Immunohistochemistry detecting human IgG may give first 
information of the magnitude and extent of intraparenchymal 
IgG deposition. Insufficient volume or less IgG concentration 
may result in only partial application in small areas in the hip-
pocampus. To ensure adequate concentration and allocation of 
IgG solutions in most of the hippocampal compartment, at least 
two injection sites, e.g., in the CA3 region and in the dentate gyrus 
should be selected. As we tested, IgG deposits can be identified up 
to 1 week after injection. We did not observe any obvious immune 
cell infiltration or activation.
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Together, we here describe a method of reliable, target-
specific IgG application into the hippocampal compartment. This 
is suited for subsequent electrophysiological and histological 
analyses as an additional and complementary method of passive-
transfer applications in mice. With this procedure, direct aAB-
induced alternations of neuronal and synaptic activity can be 
investigated in vivo and in slice preparations. In case of aAB to 
GAD65, inhibitory transmission can be evaluated by recording 
the BC–GC synapse. In addition, this procedure can also be 
applied for investigation of aAB-induced dysfunction of excita-
tory transmission, e.g., induced by aAB to the NMDA- or AMPA 
receptor. For testing glutamatergic transmission, stimulation 
of perforant path fibers and recording in GC or stimulation of 
Schaffer collaterals and recording from CA1 pyramidal neurons 
would be suitable. Moreover, field potential measurements 
for analysis of long term potentiation after IgG injection can 
be performed to obtain information about plasticity changes 
induced by aAB.
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